[{"orgOrder":0,"company":"Judo Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Judo Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Judo Bio \/ Atlas Venture","highestDevelopmentStatusID":"14","companyTruncated":"Judo Bio \/ Atlas Venture"}]

Find Clinical Drug Pipeline Developments & Deals by Judo Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds from the financing will be used to advance the lead ligand-siRNA conjugate to the clinic and to further build the proprietary STRIKE platform for the treatment of kidney diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : RNA-based Therapy

                          Therapeutic Area : Nephrology

                          Highest Development Status : Preclinical

                          Sponsor : Atlas Venture

                          Deal Size : $100.0 million

                          Deal Type : Series A Financing

                          blank